Skip to content

Study on the Effects of Mutations Under Inherited Retinal Disease in Korean

Study on the Effects of Mutations Under Inherited Retinal Disease in Korean

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03613948
Enrollment
280
Registered
2018-08-03
Start date
2018-04-10
Completion date
2021-01-20
Last updated
2021-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inherited Retinal Dystrophy Primarily Involving Retinal Pigment Epithelium, Inherited Retinal Dystrophy Primarily Involving Sensory Retina

Brief summary

To develop comprehensive genetic maps of inherited retinal diseases in Korean * Establishment of comprehensive genetic database in Koreans with inherited retinal diseases including frequently mutated genes, genotype-phenotype correlations, and visual prognosis.

Detailed description

Group/ Cohort Label : Subject with age between 6 months and 65 years who have not receive molecular genetic testing Group / Cohort Description : Consecutive subjects with inherited retinal disease who are willing to do genetic testing using whole exome sequencing (n=265) and whole genome sequencing (n=15) and agree to informed consent of the study

Interventions

None listed

Sponsors

Gangnam Severance Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
4 Months to 75 Years
Healthy volunteers
No

Inclusion criteria

* Inherited retinal disease * Age between 4 months and 75 years * Subject who has clinically confirmed visual impairment including night blindness or photophobia. Subject should meet one of the following criteria * pigmentary retinopathy in both eyes * reduced response in photopic or scotopic electroretinogram in both eyes * photoreceptor degeneration in optical coherence tomography in both eyes

Exclusion criteria

* unilateral retinal disease * Subject who had previously confirmed genetic testing * Age less than 4 months or more than 75 years * When congenital infection or trauma are suspicious for the cause of retinal disease * When age-related macular degeneration, myopic degeneration, autoimmune origin are suspicious for the cause of retinal disease * No visual impairment or normal electroretinogram (e.g., benign fleck) * Illiterate subject who can not understand informed consent * Foreigners

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic rate of whole exome sequencing (n=265) in Koreans with inherited retinal disease3 years (until December 31, 2020)patients were grouped in 1) probable molecular diagnosis: patients with pathogenic or likely pathogenic disease-associated variant(s), 2) possible molecular diagnosis: patients with 2 heterozygous mutations without segregation analysis, or patients harboring a single pathogenic or likely pathogenic disease-associated variant in a gene linked with recessive traits, provided the patient phenotype matches the known spectrum of clinical features for this gene, 3) unsolved: all other patients for which no pathogenic or likely pathogenic disease-associated variants were detected.

Secondary

MeasureTime frameDescription
Diagnostic rate of whole genome sequencing (n=15) in Koreans with inherited retinal disease3 years (until December 31, 2020)patients were grouped in 1) probable molecular diagnosis: patients with pathogenic or likely pathogenic disease-associated variant(s), 2) possible molecular diagnosis: patients with 2 heterozygous mutations without segregation analysis, or patients harboring a single pathogenic or likely pathogenic disease-associated variant in a gene linked with recessive traits, provided the patient phenotype matches the known spectrum of clinical features for this gene, 3) unsolved: all other patients for which no pathogenic or likely pathogenic disease-associated variants were detected.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026